Truist Financial Corp Kura Oncology, Inc. Transaction History

Truist Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$11.78 - $16.98 $192,932 - $278,098	-16,378 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$15.42 - $21.72 $724 - $1,020	-47 Reduced 0.29%	16,378 $307,000
Q2 2021 Aug 16, 2021	SELL	$20.85 - $29.88 $500 - $717	-24 Reduced 0.15%	16,425 $342,000
Q4 2020 Nov 19, 2021	SELL	$29.0 - $41.62 $128,325 - $184,168	-4,425 Reduced 21.2%	16,449 $537,000
Q4 2020 Feb 18, 2021	BUY	$29.0 - $41.62 $128,325 - $184,168	4,425 Added 26.9%	20,874 $682,000
Q2 2020 Aug 14, 2020	SELL	$7.95 - $18.81 $111 - $263	-14 Reduced 0.09%	16,449 $268,000
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $213,525 - $262,420	16,463 New	16,463 $227,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.